Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Coverage For Non-IND Drug Trials Should Continue – PhRMA & BIO

Executive Summary

The drug industry is pushing for continued Medicare coverage of pharmaceutical research that is not subject to the FDA's investigational new drug requirements as CMS begins to revise its Medicare clinical trials policy
Advertisement

Related Content

Clinical Trials Can Charge For Using Competitor Drugs Under FDA Proposed Rule
Clinical Trials Can Charge For Using Competitor Drugs Under FDA Proposed Rule
CMS Splits Coverage With Evidence Development Into Two Categories
CMS Splits Coverage With Evidence Development Into Two Categories
Advertisement
UsernamePublicRestriction

Register

PS047516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel